IMNM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
90.4M
+15.6%
78.1M
+31.7%
59.3M
-18.6%
72.9M
+21.2%
60.1M
R&D
69.5M
+16.1%
59.9M
+29.1%
46.4M
-23.7%
60.8M
+23.5%
49.2M
SG&A
20.9M
+14.3%
18.3M
+40.9%
12.9M
+7.1%
12.1M
+10.5%
10.9M
Operating Income
-90362000
-15.6%
-78135000
-31.7%
-59331000
+18.6%
-72861000
-21.2%
-60138000
EBITDA
-89358000
-15.8%
-77178000
-31.4%
-58728000
+18.7%
-72232000
-21.3%
-59549000
Net Income
-85783000
-17.3%
-73127000
-35.8%
-53839000
+23.0%
-69900000
-21.7%
-57457000
EPS (Basic)
$-0.76
-16.9%
$-0.65
-35.4%
$-0.48
+35.1%
$-0.74
-13.8%
$-0.65
EPS (Diluted)
$-0.76
-16.9%
$-0.65
-35.4%
$-0.48
+35.1%
$-0.74
-13.8%
$-0.65
Shares (Diluted)
113.6M
+0.3%
113.3M
+0.1%
113.1M
+19.1%
95.0M
+8.0%
88.0M
Immunome (IMNM) — Financials